pirenzepine has been researched along with Body Weight in 34 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 9.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 9.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 9.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone." | 9.10 | Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003) |
| "We conducted a prospective, controlled, open study comparing body weight, fat mass, and indices of insulin resistance/ sensitivity in 10 olanzapine-treated patients with ICD-10 schizophrenia (olanzapine dose range, 7." | 9.10 | Olanzapine induces insulin resistance: results from a prospective study. ( Ebenbichler, CF; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Laimer, M; Lechleitner, M; Mangweth, B; Patsch, JR; Weiss, E, 2003) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 9.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 9.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 7.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 7.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| "In view of the important role played by the cholinergic system in the neural regulation of growth hormone (GH) secretion, the ability of pirenzepine, a selective antagonist of muscarinic cholinergic receptors, to blunt the GH response to GH-releasing hormone (GHRH) was studied in adolescent females with anorexia nervosa in the acute (AN-AP) five AN-AP patients, administration of GHRH 1-40 (1 microgram/kg IV) evoked a significantly higher GH response than in controls at established intervals, whereas in eight AN-RP and seven AED patients it was higher than in controls at only one (150-min) and two (150-min, 180-min) time intervals, respectively." | 7.68 | Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. ( Andreoni, A; Belliti, D; Cristofani, R; Ferdeghini, M; Müller, EE; Rolla, M, 1991) |
| "Clozapine has been the gold standard for treatment of patients with refractory schizophrenia but is associated with serious safety liabilities." | 5.11 | Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. ( Banki, CM; Bartko, G; Bitter, I; Breier, A; Brook, S; Dossenbach, MR; Feldman, PD; Füredi, J; Gagiano, CA; Janka, Z; Kovacs, G; Metcalfe, S, 2004) |
| "To compare the efficacy and safety of the atypical antipsychotics amisulpride and olanzapine in the treatment of acute psychotic exacerbations of schizophrenia." | 5.10 | A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. ( Fleurot, O; Giudicelli, A; Lĵo, H; Martin, S; Peuskens, J; Rein, W; Thirumalai, S, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 5.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "The primary objective of this study was to evaluate insulin sensitivity in healthy subjects treated with olanzapine or risperidone." | 5.10 | Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. ( Breier, A; Carlson, C; Cavazzoni, P; Chinnapongse, S; Dananberg, J; Davis, T; Henry, RR; Mudaliar, S; Mukhopadhyay, N; Ray, A; Sowell, M, 2003) |
| "We conducted a prospective, controlled, open study comparing body weight, fat mass, and indices of insulin resistance/ sensitivity in 10 olanzapine-treated patients with ICD-10 schizophrenia (olanzapine dose range, 7." | 5.10 | Olanzapine induces insulin resistance: results from a prospective study. ( Ebenbichler, CF; Eder, U; Fleischhacker, WW; Hofer, A; Hummer, M; Kemmler, G; Laimer, M; Lechleitner, M; Mangweth, B; Patsch, JR; Weiss, E, 2003) |
| "A retrospective study of the Massachusetts General Hospital Bipolar Clinic database was carried out to identify 50 consecutive treatment trials in patients with DSM-IV bipolar disorder type I who had received adjunctive treatment with risperidone, olanzapine, or clozapine, along with standard mood stabilizers." | 5.09 | A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. ( Ghaemi, SN; Guille, C; Sachs, GS, 2000) |
| "Weight change and the weight-related health factors of nonfasting serum glucose, serum cholesterol, and diastolic blood pressure levels were analyzed in patients with DSM-III-R schizophrenia and related disorders who received treatment with olanzapine for up to 3 years, and comparisons were made to patients treated with haloperidol." | 5.09 | Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. ( Basson, BR; Gilmore, JA; Kinon, BJ; Tollefson, GD, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "Several clinical reports have demonstrated that most antipsychotics of the new generation, but not the typical antipsychotic haloperidol, induce weight gain in schizophrenic patients." | 3.72 | Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. ( Kreilgaard, M; Mow, T; Pouzet, B; Velschow, S, 2003) |
| "The changes in extracellular acetylcholine levels were investigated by microdialysis in the cortex and hippocampus of aging rats after administration of metrifonate (80 mg/kg), rivastigmine (0." | 3.71 | Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats. ( Bellucci, A; Casamenti, F; Costagli, C; Pepeu, G; Scali, C; Schmidt, B, 2002) |
| "Weight gain induced by clozapine or olanzapine appears to be associated with an increase in leptin level that cannot be attributed to dietary changes upon hospitalization." | 3.70 | Body weight and leptin plasma levels during treatment with antipsychotic drugs. ( Haack, M; Hinze-Selch, D; Kraus, T; Kühn, M; Pollmächer, T; Schuld, A; Uhr, M, 1999) |
| "Fourteen patients on treatment with olanzapine (all meeting DSM-IV criteria for schizophrenia or related psychoses) were studied." | 3.70 | Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. ( Brismar, KE; Hulting, AL; Melkersson, KI, 2000) |
| "In view of the important role played by the cholinergic system in the neural regulation of growth hormone (GH) secretion, the ability of pirenzepine, a selective antagonist of muscarinic cholinergic receptors, to blunt the GH response to GH-releasing hormone (GHRH) was studied in adolescent females with anorexia nervosa in the acute (AN-AP) five AN-AP patients, administration of GHRH 1-40 (1 microgram/kg IV) evoked a significantly higher GH response than in controls at established intervals, whereas in eight AN-RP and seven AED patients it was higher than in controls at only one (150-min) and two (150-min, 180-min) time intervals, respectively." | 3.68 | Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. ( Andreoni, A; Belliti, D; Cristofani, R; Ferdeghini, M; Müller, EE; Rolla, M, 1991) |
| "Olanzapine is an atypical neuroleptic drug with mood-stabilising properties and few of the side effects commonly associated with conventional neuroleptic treatment." | 2.70 | A clinical case series of six extremely aggressive youths treated with olanzapine. ( Gillberg, C; Rastam, M; Soderstrom, H, 2002) |
| " We have evaluated the consequences of HFD on heart rate (HR) and blood pressure (BP) circadian cycles and methylscopolamine dose-response curves." | 1.30 | Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension. ( Berlan, M; Galitzky, J; Merial, C; Montastruc, JL; Pelat, M; Senard, JM; Verwaerde, P, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 8 (23.53) | 18.2507 |
| 2000's | 24 (70.59) | 29.6817 |
| 2010's | 1 (2.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Zhao, Y | 1 |
| Shao, H | 1 |
| Zheng, X | 1 |
| Scali, C | 1 |
| Casamenti, F | 1 |
| Bellucci, A | 1 |
| Costagli, C | 1 |
| Schmidt, B | 1 |
| Pepeu, G | 1 |
| Kozian, R | 1 |
| Soderstrom, H | 1 |
| Rastam, M | 1 |
| Gillberg, C | 1 |
| Martin, S | 1 |
| Lĵo, H | 1 |
| Peuskens, J | 1 |
| Thirumalai, S | 1 |
| Giudicelli, A | 1 |
| Fleurot, O | 1 |
| Rein, W | 1 |
| Rodríguez-Pérez, V | 1 |
| López, A | 3 |
| Blanco, C | 1 |
| Peña, C | 1 |
| Abel, A | 1 |
| Gómez, Y | 1 |
| Ferreiro, MJ | 1 |
| Rego, C | 1 |
| Cudeiro, F | 1 |
| Alvarez, V | 1 |
| Prieto, R | 1 |
| Ciudad, A | 1 |
| Pouzet, B | 1 |
| Mow, T | 1 |
| Kreilgaard, M | 1 |
| Velschow, S | 1 |
| Wetterling, T | 1 |
| Horowitz, JM | 1 |
| Goyal, A | 1 |
| Ramdeen, N | 1 |
| Hallas, BH | 1 |
| Horowitz, AT | 1 |
| Torres, G | 1 |
| Sowell, M | 1 |
| Mukhopadhyay, N | 1 |
| Cavazzoni, P | 1 |
| Carlson, C | 1 |
| Mudaliar, S | 1 |
| Chinnapongse, S | 1 |
| Ray, A | 1 |
| Davis, T | 1 |
| Breier, A | 2 |
| Henry, RR | 1 |
| Dananberg, J | 1 |
| Bitter, I | 1 |
| Dossenbach, MR | 1 |
| Brook, S | 1 |
| Feldman, PD | 1 |
| Metcalfe, S | 1 |
| Gagiano, CA | 1 |
| Füredi, J | 1 |
| Bartko, G | 1 |
| Janka, Z | 1 |
| Banki, CM | 1 |
| Kovacs, G | 1 |
| Ebenbichler, CF | 1 |
| Laimer, M | 1 |
| Eder, U | 1 |
| Mangweth, B | 1 |
| Weiss, E | 1 |
| Hofer, A | 1 |
| Hummer, M | 1 |
| Kemmler, G | 1 |
| Lechleitner, M | 1 |
| Patsch, JR | 1 |
| Fleischhacker, WW | 1 |
| de la Pierre, M | 1 |
| Aricò, S | 1 |
| Capussotti, L | 1 |
| Dellepiane, M | 1 |
| Marucci, M | 1 |
| Gandini, G | 1 |
| Imarisio, P | 1 |
| Fukomoto, Y | 1 |
| Yoshida, M | 1 |
| Weiss, RM | 1 |
| Latifpour, J | 1 |
| Zhang, LC | 2 |
| Buccafusco, JJ | 2 |
| Kraus, T | 1 |
| Haack, M | 1 |
| Schuld, A | 1 |
| Hinze-Selch, D | 1 |
| Kühn, M | 1 |
| Uhr, M | 1 |
| Pollmächer, T | 1 |
| Pelat, M | 1 |
| Verwaerde, P | 1 |
| Merial, C | 1 |
| Galitzky, J | 1 |
| Berlan, M | 1 |
| Montastruc, JL | 1 |
| Senard, JM | 1 |
| Guille, C | 1 |
| Sachs, GS | 1 |
| Ghaemi, SN | 1 |
| Melkersson, KI | 1 |
| Hulting, AL | 1 |
| Brismar, KE | 1 |
| Tollefson, GD | 3 |
| Birkett, MA | 1 |
| Kiesler, GM | 1 |
| Wood, AJ | 1 |
| Bouchard, RH | 1 |
| Demers, MF | 1 |
| Simoneau, I | 1 |
| Alméras, N | 1 |
| Villeneuve, J | 1 |
| Mottard, JP | 1 |
| Cadrin, C | 1 |
| Lemieux, I | 1 |
| Després, JP | 1 |
| Kinon, BJ | 2 |
| Basson, BR | 2 |
| Gilmore, JA | 2 |
| Taylor, CC | 1 |
| Szymanski, KA | 1 |
| Dewan, VK | 1 |
| Baptista, T | 1 |
| Beaulieu, S | 1 |
| Matsui, S | 1 |
| Fu, ML | 1 |
| Hayase, M | 1 |
| Katsuda, S | 1 |
| Yamaguchi, N | 1 |
| Teraoka, K | 1 |
| Kurihara, T | 1 |
| Takekoshi, N | 1 |
| Ramankutty, G | 1 |
| Meyer, JM | 1 |
| Opp, D | 1 |
| Hildebrandt, C | 1 |
| Lim, DK | 1 |
| Hoskins, B | 1 |
| Ho, IK | 1 |
| Arce, VM | 1 |
| Cella, SG | 1 |
| Locatelli, V | 1 |
| Müller, EE | 2 |
| Rolla, M | 1 |
| Andreoni, A | 1 |
| Belliti, D | 1 |
| Cristofani, R | 1 |
| Ferdeghini, M | 1 |
| Sala, M | 1 |
| Braida, D | 1 |
| Calcaterra, P | 1 |
| Leone, MP | 1 |
| Comotti, FA | 1 |
| Gianola, S | 1 |
| Gori, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
1 review available for pirenzepine and Body Weight
| Article | Year |
|---|---|
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Humans; Hy | 2003 |
10 trials available for pirenzepine and Body Weight
| Article | Year |
|---|---|
A clinical case series of six extremely aggressive youths treated with olanzapine.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Benzodiazepines; Body Weight; Conduct Disorder; | 2002 |
A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; B | 2002 |
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Chronic Disease; Drug Re | 2002 |
Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Fasting; Fatty Acids, None | 2003 |
Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; | 2004 |
Olanzapine induces insulin resistance: results from a prospective study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Composition; Body Weight; Dose-Res | 2003 |
A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Body Weight; | 2000 |
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Weight; Clozapine; Double-Blind M | 2001 |
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Body Mass Index; Body W | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
23 other studies available for pirenzepine and Body Weight
| Article | Year |
|---|---|
Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes.
Topics: Animals; Benzodiazepines; Blood Glucose; Body Weight; Dyslipidemias; Energy Metabolism; Fatty Liver; | 2019 |
Effect of subchronic administration of metrifonate, rivastigmine and donepezil on brain acetylcholine in aged F344 rats.
Topics: Acetylcholine; Aging; Animals; Body Weight; Brain; Carbamates; Cerebral Cortex; Cholinesterase Inhib | 2002 |
[Olanzapine-induced diabetes mellitus].
Topics: Adult; Benzodiazepines; Body Weight; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Dose-Response | 2002 |
Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Diet; Disease Models, Animal; Dose-Resp | 2003 |
Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Behavior, Animal; Benzodiaz | 2003 |
[Description of a case of Zollinger-Ellison syndrome].
Topics: Benzodiazepinones; Body Weight; Cimetidine; Diarrhea; Female; Gastrectomy; Gastric Acid; Humans; Mid | 1984 |
Reversibility of diabetes- and diuresis-induced alterations in rat bladder dome muscarinic receptors.
Topics: Animals; Binding, Competitive; Body Weight; Cell Membrane; Diabetes Mellitus, Experimental; Diamines | 1994 |
Prevention of morphine-induced muscarinic (M2) receptor adaptation suppresses the expression of withdrawal symptoms.
Topics: Animals; Behavior, Animal; Blood Pressure; Body Weight; Disease Models, Animal; Infusions, Intraveno | 1998 |
Body weight and leptin plasma levels during treatment with antipsychotic drugs.
Topics: Adipose Tissue; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 1999 |
Impaired atrial M(2)-cholinoceptor function in obesity-related hypertension.
Topics: Adenylyl Cyclases; Animals; Blood Pressure; Body Weight; Dogs; Dose-Response Relationship, Drug; Hea | 1999 |
Adaptive changes in M1 muscarinic receptors localized to specific rostral brain regions during and after morphine withdrawal.
Topics: Animals; Autoradiography; Binding, Competitive; Blood Pressure; Body Weight; Brain; Isoflurophate; M | 2000 |
Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Chromatography, High Press | 2000 |
Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Cardiovascular Diseases; Cross-Sectional | 2001 |
Re: Weight change with antipsychotic use.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Fructose; Humans; Male; Olanzapin | 2001 |
Body weight gain, insulin, and leptin in olanzapine-treated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic | 2001 |
Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor.
Topics: Animals; Anti-Arrhythmia Agents; Autoimmune Diseases; Blood Pressure; Body Weight; Cardiomyopathy, D | 2001 |
Olanzapine-induced destabilization of diabetes in the absence of weight gain.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Diabetes Complications; Diabetes | 2002 |
A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Topics: Adult; Aged; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weight; Dia | 2002 |
Olanzapine-associated type 2 diabetes mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Weight; Diabetes Mellitus, Type | 2002 |
Trihexyphenidyl enhances physostigmine prophylaxis against soman poisoning in guinea pigs.
Topics: Animals; Body Weight; Brain; Drinking; Drug Interactions; Guinea Pigs; Kinetics; Lethal Dose 50; Mal | 1991 |
Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
Topics: Animals; Blood Glucose; Body Weight; Dogs; Drug Interactions; Energy Intake; Female; Glucose; Growth | 1991 |
Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders.
Topics: Adolescent; Anorexia Nervosa; Body Weight; Brain; Bulimia; Estradiol; Female; Follicle Stimulating H | 1991 |
Effect of centrally administered atropine and pirenzepine on radial arm maze performance in the rat.
Topics: Animals; Atropine; Body Weight; Exploratory Behavior; Injections, Intraventricular; Male; Pirenzepin | 1991 |